Sponsor content
106 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Hepcludex (bulevirtide) is approved for treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.
-
Prescription medicine decision summaryLivdelzi (seladelpar) is approved to treat primary biliary cholangitis (PBC) in adults in combination with ursodeoxycholic acid (UDCA) when UDCA alone isn't effective, or on its own if UDCA can’t be tolerated.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIVDELZI seladelpar 10 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YEYTUO lenacapavir (as sodium) 300 mg tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YEYTUO lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vial.
-
Prescription medicine registrationActive ingredients: seladelpar lysine.
-
Prescription medicine registrationActive ingredients: lenacapavir sodium.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet bottle.
-
Cancellation by sponsorRequested by Gilead Sciences Pty Ltd
-
Prescription medicine registrationActive ingredients: bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate.